Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1962 1
1965 2
1966 1
1967 1
1969 1
1970 1
1971 4
1973 2
1974 1
1975 1
1976 1
1977 1
1980 6
1981 8
1982 2
1983 10
1984 10
1985 5
1986 6
1988 5
1989 6
1990 8
1991 12
1992 8
1993 14
1994 15
1995 10
1996 10
1997 8
1998 11
1999 14
2000 16
2001 15
2002 20
2003 17
2004 11
2005 20
2006 10
2007 26
2008 27
2009 21
2010 41
2011 38
2012 33
2013 31
2014 35
2015 31
2016 39
2017 33
2018 32
2019 48
2020 52
2021 56
2022 58
2023 51
2024 43

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

907 results

Results by year

Filters applied: . Clear all
Page 1
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. Among authors: de la fuente m. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Free PMC article. Clinical Trial.
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF, Wen PY. Mellinghoff IK, et al. Among authors: de la fuente mi. J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12. J Clin Oncol. 2020. PMID: 32530764 Free PMC article. Clinical Trial.
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. Brastianos PK, et al. Among authors: de la fuente mi. N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329. N Engl J Med. 2023. PMID: 37437144 Free PMC article. Clinical Trial.
Adult-type Diffuse Gliomas.
de la Fuente MI. de la Fuente MI. Continuum (Minneap Minn). 2023 Dec 1;29(6):1662-1679. doi: 10.1212/CON.0000000000001352. Continuum (Minneap Minn). 2023. PMID: 38085893
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V. de la Fuente MI, et al. Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139. Neuro Oncol. 2023. PMID: 35639513 Free PMC article. Clinical Trial.
Therapies for IDH-Mutant Gliomas.
Alshiekh Nasany R, de la Fuente MI. Alshiekh Nasany R, et al. Among authors: de la fuente mi. Curr Neurol Neurosci Rep. 2023 May;23(5):225-233. doi: 10.1007/s11910-023-01265-3. Epub 2023 Apr 15. Curr Neurol Neurosci Rep. 2023. PMID: 37060388 Free PMC article. Review.
[Chronodisruption and ageing].
Ortiz-Tudela E, Bonmatí-Carrión Mde L, De la Fuente M, Mendiola P. Ortiz-Tudela E, et al. Among authors: de la fuente m. Rev Esp Geriatr Gerontol. 2012 Jul-Aug;47(4):168-73. doi: 10.1016/j.regg.2011.09.013. Epub 2011 Dec 15. Rev Esp Geriatr Gerontol. 2012. PMID: 22177973 Review. Spanish.
Targeting IDH1/IDH2 mutations in gliomas.
de la Fuente MI. de la Fuente MI. Curr Opin Neurol. 2022 Dec 1;35(6):787-793. doi: 10.1097/WCO.0000000000001111. Epub 2022 Oct 21. Curr Opin Neurol. 2022. PMID: 36367045 Review.
Social environment as a modulator of immunosenescence.
Garrido A, Martínez de Toda I, Díaz Del Cerro E, Félix J, Ceprián N, González-Sánchez M, De la Fuente M. Garrido A, et al. Among authors: de la fuente m. Expert Rev Mol Med. 2022 Aug 1;24:e29. doi: 10.1017/erm.2022.24. Expert Rev Mol Med. 2022. PMID: 35912691 Review.
907 results